Ten Count Consulting’s Post

The more you learn about trends in 340B and how DSCSA impacts, the uglier it gets! Working on part 2 of our blog but it begs some questions: - Misunderstandings galore, legal actions growing, and conflicting summaries of impacts to at risk populations? - Like drug shortages, symptoms of pricing and payment opaqueness and locked reimbursement at heart of problems? Can the industry pivot to cost plus/flat pricing/non-PBM any faster? What are we missing?

AuthorityRx has crafted a solution to automate the management of ESP to ensure savings and avoid unnecessary ESP mistakes that can happen. Happy to share how managing ESP can go from one of the most frustrating tasks to simplest.

🚨 New Report Alert! 🚨 We are excited to share a recent report from our Legislation & Government Insights coverage, which highlights the pressing issue of drug shortages and the proposed legislation aimed at addressing this growing problem. Stay informed and ahead of the curve by referring to IPD Analytics’ Payer & Provider Insights and Legislation and Government Insights platforms for the latest updates on drug shortage news and legislative developments. #Healthcare #Legislation #DrugShortages #IPDAnalytics #GovernmentInsights #PayerProviderInsights

The 340B Drug Pricing Program’s rapid growth has created a complex web of financial and legislative challenges for pharma companies. My colleagues Nick Porter Neelabh Saxena Harshil Gagnani Shreya Bhatia dive into pharma’s and states’ responses to the program’s evolution and the effectiveness of these strategies. Since we drafted this whitepaper, several more manufacturers and states have evolved their policies, showing just how dynamic this space really is! Download the white paper to find out how pharma can adapt. #healthcare #pharma #340B #drugpricing #publicpolicy https://lnkd.in/eXczZneB

FDA proposes new restriction on Compounding Facilities in unpublished rule. Scheduled for publishing on March 20th, FDA has proposed a rule that would establish drug categories or specific products which are considered "demonstrably difficult" to compound ("DDC"). FDA intends to propose the first three (3) DDC categories which include Oral Solid Modified Release Drug Products That Employ Coated Systems (MRCs), Liposome Drug Products (LDPs), and Drug Products Using HMEs (a continuous process operation that achieves or is intended to achieve the molecular mixing of APIs and inactive ingredients). Compounded drug products produced using these processes would not be eligible for the exemptions provided in the FD&C Act under Sections 503A and 503B. #503A #503B #Compounding #FDA https://zurl.co/jKOs

Thoughts on this? >> Sen. Cassidy questions Lilly and Amgen on 340B restrictions on contract pharmacies >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #healthcare #productmarketing

Another installment in the disaster that is pharmacy.... Why are drugs in short supply? Most of us are beginning to understand the PBM-Pharma relationship for retail drugs, but what has not gotten much attention is the three GPOs that purchase 90% of drugs used in hospitals. Between PBMs and GPOs, companies providing generic drugs are being squeezed. They agree to produce drugs at a loss in exchange for huge volume. When the losses accumulate, they stop producing the drugs. The middlemen, rather than pay more and take a hit on their own margins, wait for another sucker to come along who will take their deal. In the meantime, drugs are unavailable to patients. This is an inefficient market with lots of small manufacturers and only a few worldwide buyers. We are starting to see Mark Cuban Cost Plus Drug Company, PBC and some hospital consortiums bring on manufacturing capacity with direct to hospital sales channels. Might be easier if GPOs paid a fair price and retained a reasonable margin.

Do you have a cash program and want to get your local media’s attention? One good thing that Mark Cuban has done is bring a lot of interest from the public to pharmacies and cash pay programs. Use this template to connect with local media and highlight your pharmacy's offerings compared to Mark Cuban Cost Drug Company. Download it here: https://lnkd.in/eGXsybkZ #diversifyrx #independentpharmacy #localpharmacy #communitypharmacy #smallpharmacyowner #smallbusinessowner #pharmacy #becomingapharmacybadass #pharmacybadassuniversity

🚀 Innovative Specialty Drug Management 🚀 Cardinal Health and Terso Solutions are revolutionizing specialty drug inventory. These advancements ensure critical medications are always in stock, reduce waste, and streamline pharmacy workflows. With specialty drug spending projected to reach $419 billion by 2025, these innovations are crucial for efficient pharmacy operations. #PharmacyTech #SpecialtyDrugs #HealthcareInnovation

Have you come across Limited Distribution Drugs (LDD)? These medications frequently raise issues surrounding safety, availability, or high costs. Marsh McLennan Agency examines why they demand specialized distribution strategies and handling protocols in their recent blog. #Pharmacy #Medicine